Second complete once-daily single tablet therapy in development.
D019380:Anti-HIV Agents / Q000008:administration & dosage; D017326:Clinical Trials, Phase III as Topic; D003841:Deoxycytidine / Q000008:administration & dosage / Q000031:analogs & derivatives*; D004338:Drug Combinations; D000069480:Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination; D015658:HIV Infections / Q000188:drug therapy*; D054303:HIV Reverse Transcriptase / Q000037:antagonists & inhibitors*; D006801:Humans; D009570:Nitriles / Q000008:administration & dosage; D009943:Organophosphorus Compounds / Q000008:administration & dosage; D011743:Pyrimidines / Q000008:administration & dosage; D000068696:Rilpivirine; D013607:Tablets / Q000008:administration & dosage
D019380:Anti-HIV Agents; D004338:Drug Combinations; D000069480:Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination; D009570:Nitriles; D009943:Organophosphorus Compounds; D011743:Pyrimidines; D013607:Tablets; D003841:Deoxycytidine; D054303:HIV Reverse Transcriptase; D000068696:Rilpivirine